Tomas Mikael Mustelin

age ~65

from Seattle, WA

Get Report
Also known as:
  • Tomas M Mustelin
  • Julie I Mustelin
  • Julie L Mustelin
  • Thomas M Mustelin
  • Tomas N
  • Tom Mustelin
  • Julie Baumgartner
  • Thomas N
  • Julie Ramsey
  • Jane Coats
Phone and address:
3223 Perkins Ln W, Seattle, WA 98199
2064737883
Related to:
Connected to:

Tomas Mustelin Phones & Addresses

  • 3223 Perkins Ln W, Seattle, WA 98199 • 2064737883
  • 1554 28Th Ave W, Seattle, WA 98199 • 2064202036 • 5096560325
  • Rockville, MD
  • Easton, WA
  • 11308 Caminito Aclara, San Diego, CA 92126 • 8586356760
  • Kittitas, WA
  • 11904 Tallwood Ct, Potomac, MD 20854 • 2064202036

Work

  • Company:
    Medimmune
    Jul 2012
  • Position:
    Interim head of research

Education

  • Degree:
    PhD
  • School / High School:
    Helsingin yliopisto
    1985 to 1987
  • Specialities:
    Signal Transduction

Skills

Immunology • Drug Discovery • Biotechnology • Drug Development • Cell Biology • Cancer • Translational Research • Signal Transduction • Clinical Trials • Genomics • Genetics • Molecular Biology • Inflammation • Biomarkers • Lifesciences • Cell Signaling • Clinical Research • Cell • Biochemistry • Biopharmaceuticals • Cell Culture • In Vivo • Antibodies • Translational Medicine • Animal Models • Protein Chemistry • Protein Expression • In Vitro • Infectious Diseases • High Throughput Screening • Protein Purification • Assay Development • Monoclonal Antibodies • Flow Cytometry • Immunohistochemistry • Therapists • Clinical Development • Oncology • Tissue Culture • Pharmacology • Elisa • Vaccines • Therapeutics • Cancer Research • Neuroscience • Virology • Western Blotting • Immunoassays • Immunoprecipitation • Toxicology

Industries

Biotechnology

Resumes

Tomas Mustelin Photo 1

Professor Of Medicine

view source
Location:
Washington, DC
Industry:
Biotechnology
Work:
Medimmune since Jul 2012
Interim Head of Research
MedImmune - Gaithersburg, MD since Jan 2012
Vice President Research, Respiratory, Inflammatory, and Autoimmune diseases
UC San Diego since 2011
Member of the UCSD Clinical and Translational Research Institute (CTRI)
Burnham Institute since 2007
Adjunct Professor
UCSD since Jun 2007
Adjunct Professor
Education:
Helsingin yliopisto 1985 - 1987
PhD, Signal Transduction Helsingin yliopisto 1981 - 1987
MD, Medicine
Skills:
Immunology
Drug Discovery
Biotechnology
Drug Development
Cell Biology
Cancer
Translational Research
Signal Transduction
Clinical Trials
Genomics
Genetics
Molecular Biology
Inflammation
Biomarkers
Lifesciences
Cell Signaling
Clinical Research
Cell
Biochemistry
Biopharmaceuticals
Cell Culture
In Vivo
Antibodies
Translational Medicine
Animal Models
Protein Chemistry
Protein Expression
In Vitro
Infectious Diseases
High Throughput Screening
Protein Purification
Assay Development
Monoclonal Antibodies
Flow Cytometry
Immunohistochemistry
Therapists
Clinical Development
Oncology
Tissue Culture
Pharmacology
Elisa
Vaccines
Therapeutics
Cancer Research
Neuroscience
Virology
Western Blotting
Immunoassays
Immunoprecipitation
Toxicology

Us Patents

  • Functional Variant Of Lymphoid Tyrosine Phosphatase Is Associated With Autoimmune Disorders

    view source
  • US Patent:
    20080199514, Aug 21, 2008
  • Filed:
    Jul 11, 2005
  • Appl. No.:
    11/571711
  • Inventors:
    Tomas Mikael Mustelin - San Diego CA, US
    Nunzio Bottini - Pasadena CA, US
  • Assignee:
    THE BURNHAM INSTITUTE - La Jolla CA
  • International Classification:
    C12Q 1/42
    C12Q 1/68
    G01N 33/50
    A61K 31/70
    A61K 39/395
    C12N 9/16
    C12N 15/52
    A61K 31/7088
    A61K 9/127
    A61K 38/02
    C12Q 1/02
  • US Classification:
    424450, 435 6, 435 29, 435 21, 435 71, 435 792, 514 2, 514 23, 4241301, 514 44, 435196, 536 232
  • Abstract:
    The invention is the discovery of a single nucleotide polymorphism in the gene coding for lymphoid tyrosine phosphatase. This SNP leads to a mutation in the lymphoid tyrosine phosphatase protein that prohibits binding with the SH3 domain of Csk, and leads to a subsequent dysregulation of the T-Cell activation cascade. Such dysregulation can lead to a variety of autoimmune disorders. Thus, the invention provides a series of useful methods for diagnosing, discovering modulators, developing treatments and providing research tools. Also, the invention provides compositions of matter useful for research and useful for the diagnosis and treatment of these disorders.

  • Methods For Treating Leukemia And Myelodysplastic Syndrome, And Methods For Identifying Agents For Treating Same

    view source
  • US Patent:
    20090105240, Apr 23, 2009
  • Filed:
    Oct 17, 2007
  • Appl. No.:
    11/975082
  • Inventors:
    Tomas Mustelin - Seattle WA, US
    Lutz Tautz - La Jolla CA, US
    Nicholas David Peter Cosford - La Jolla CA, US
    Eduard Sergienko - La Jolla CA, US
  • International Classification:
    A61K 31/53
    A61K 31/47
    A61K 31/435
    A61K 31/453
    A61K 31/5377
    A61P 35/02
    C12Q 1/42
    A61K 31/433
    A61K 31/42
    A61K 31/439
  • US Classification:
    5142315, 514312, 514290, 514326, 514363, 514380, 514304, 514242, 435 21
  • Abstract:
    The present disclosure relates to methods for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure further relates to compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure also relates to methods for identifying compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome.

  • Vhr Protein Tyrosine Phosphatase Inhibitors, Compositions And Methods Of Use

    view source
  • US Patent:
    20090105254, Apr 23, 2009
  • Filed:
    Oct 17, 2008
  • Appl. No.:
    12/253804
  • Inventors:
    Tomas Mustelin - La Jolla CA, US
    Lutz Tautz - La Jolla CA, US
  • Assignee:
    BURNHAM INSTITUTE FOR MEDICAL RESEARCH - La Jolla CA
  • International Classification:
    A61K 31/427
    A61P 35/00
    C07D 417/06
    A61K 31/5377
    A61K 31/454
    A61K 31/426
  • US Classification:
    5142365, 548183, 514369, 514326
  • Abstract:
    Disclosed herein are H1-related (VHR) protein tyrosine phosphatase (PTP) inhibitors that provide a method for treating cancer.

  • Compositions And Methods For Treatment Of Disease Caused By Yersinia Spp Infection

    view source
  • US Patent:
    20090312352, Dec 17, 2009
  • Filed:
    Oct 19, 2005
  • Appl. No.:
    11/577591
  • Inventors:
    Tomas Mikael Mustelin - La Jolla CA, US
    Maurizio Pellecchia - La Jolla CA, US
    Lutz Tautz - La Jolla CA, US
  • International Classification:
    A61K 31/506
    C07D 405/06
    C07D 417/14
    A61K 31/429
    A61K 31/41
    C07D 405/12
    C07D 307/02
    A61K 31/341
    A61K 31/4196
    A61K 31/427
    A61P 31/10
  • US Classification:
    514274, 544300, 548151, 514366, 514382, 548253, 549501, 514461, 514383, 5482648, 548183, 514369
  • Abstract:
    The invention generally relates to compositions and methods for treatment of disease caused by spp. infection. More specifically, the invention relates to protein tyrosine phosphatase inhibitors and derivatives and analogs thereof, pharmaceutical compositions containing the protein tyrosine phosphatase inhibitors and analogs, methods of making the protein tyrosine phosphatase inhibitors and analogs and methods of use thereof.

  • Ang-2 Inhibition To Treat Multiple Sclerosis

    view source
  • US Patent:
    20110158978, Jun 30, 2011
  • Filed:
    Dec 23, 2010
  • Appl. No.:
    12/977991
  • Inventors:
    Jacqueline A. Kirchner - Seattle WA, US
    Tomas Mikael Mustelin - Seattle WA, US
  • Assignee:
    AMGEN INC. - Thousand Oaks CA
  • International Classification:
    A61K 39/395
    A61P 25/28
  • US Classification:
    4241301
  • Abstract:
    Methods and compositions are disclosed for treating multiple sclerosis in a human subject by administering a therapeutically effective amount of an H4L4 antibody or a 2XCon4(C) peptibody.

  • Methods For Treating Leukemia And Myelodysplastic Syndrome, And Methods For Identifying Agents For Treating Same

    view source
  • US Patent:
    20120095032, Apr 19, 2012
  • Filed:
    Dec 6, 2011
  • Appl. No.:
    13/312391
  • Inventors:
    Tomas Mustelin - Seattle WA, US
    Lutz Tautz - San Diego CA, US
    Nicolas David Peter Cosford - San Diego CA, US
    Eduard Sergienko - San Diego CA, US
  • International Classification:
    A61K 31/437
    C12N 5/10
    C12N 5/071
    A61P 35/02
    A61P 7/00
  • US Classification:
    514293, 435375
  • Abstract:
    The present disclosure relates to methods for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure further relates to compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure also relates to methods for identifying compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome.

  • Novel Il33 Form, Mutated Forms Of Il33, Antibodies, Assays And Methods Of Using The Same

    view source
  • US Patent:
    20200353078, Nov 12, 2020
  • Filed:
    Apr 10, 2020
  • Appl. No.:
    16/845121
  • Inventors:
    Emma S. Cohen - Cambridge, GB
    David C. Lowe - Cambridge, GB
    Robin Butler - Cambridge, GB
    Ian C. Scott - Cambridge, GB
    Katherine A. Vousden - Cambridge, GB
    Martin D. Strain - Cambridge, GB
    Sara Carmen - Cambridge, GB
    Elizabeth H. England - Cambridge, GB
    Benjamin P. Kemp - Cambridge, GB
    David G. Rees - Cambridge, GB
    Catherine L. Overed-Sayer - Cambridge, GB
    Tomas M. Mustelin - Gaithersburg MD, US
    Matthew Sleeman - Cambridge, GB
    Kirsty Houslay - Cambridge, GB
  • International Classification:
    A61K 39/395
    C07K 16/24
    A01K 67/027
    C07K 14/54
    A61P 11/06
  • Abstract:
    The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.

  • Anti-Pad4 Autoantibodies As Clinical Response Biomarkers For The Treatment Of Rheumatoid Arthritis

    view source
  • US Patent:
    20200317793, Oct 8, 2020
  • Filed:
    May 23, 2017
  • Appl. No.:
    16/304055
  • Inventors:
    - Cambridge, Cambridgeshire, GB
    Alex GODWOOD - Cambridge, GB
    Ethan Paul GRANT - Gaithersburg MD, US
    Martin Michael Kari SCHWICKART - Gaithersburg MD, US
    Carlos CHAVEZ - Gaithersburg MD, US
    Meina LIANG - Gaithersburg MD, US
    Tomas Mikael MUSTELIN - Seattle WA, US
    Zhengbin YAO - Gaithersburg MD, US
    Koustubh RANADE - Gaithersburg MD, US
  • International Classification:
    C07K 16/28
    G01N 33/68
    G01N 33/564
  • Abstract:
    The present disclosure relates to the use of anti-PAD4 autoantibodies as a clinical biomarker for rheumatoid arthritis (RA) treatment. The disclosure further provides an assay to detect anti-PAD4 autoantibodies, assay kits for the detection of anti-PAD4 autoantibodies, as well as computer implemented diagnostic methods.

Facebook

Tomas Mustelin Photo 2

Tomas Mustelin

view source
Friends:
Kristin Gladfelter, Patrik Engstrm, Lars-Peter Donner, Klaus Korpela

Youtube

Rewriting the etiology and pathogenesis of rh...

Rewriting the etiology and pathogenesis of rheumat...

Department of Medicine Grand Rounds Presentation by Dr. Tomas Mustelin...

  • Duration:
    57m 57s

11/01/22 Eosinophils as Mediators of Rheumato...

11/01/22 Eosinophils as Mediators of Rheumatologic...

Thomas Mustelin, MD, PhD, Professor of Medicine, Chief of Rheumatology...

  • Duration:
    1h 4m 3s

Approaches to SARS-CoV-2 Sample Processing fo...

Approaches to SARS-CoV-2 Sample Processing for RNA...

... Kinet's laboratory at Harvard Medical School and Dr. Tomas Musteli...

  • Duration:
    58m 11s

Nikon D5100 with 105mm f/2.8 lens samples

Nikon D5100 with 105mm f/2.8 lens samples

... help from Ilona Lozer, Carl Barrentine and Tomas Mustelin) by Wild...

  • Duration:
    2m 29s

How to Mountain Bike Safer, Smarter and Bette...

How to Mountain Bike Safer, Smarter and Better | M...

And to follow Instagram for more content: @remymetailler See you on th...

  • Duration:
    22m 40s

Behind the Scenes: Red Bull Mine Line with Th...

Behind the Scenes: Red Bull Mine Line with Thomas ...

In his latest Red Bull film project Mine Line, Thomas honors his coal ...

  • Duration:
    12m 22s
Get Report for Tomas Mikael Mustelin from Seattle, WA, age ~65
Control profile